孟鲁司特钠联合双歧杆菌四联活菌片 对小儿过敏性紫癜的疗效

摘要：目的 对孟鲁司特钠联合双歧杆菌四联活菌片治疗小儿过敏性紫癜的临床疗效进行分析。方法 选取2015年3月1日至2018年3月31日我院收治的96例过敏性紫癜患儿为研究对象，依据随机数字表法分为A组、B组、C组、D组，每组24例。A组患儿施以常规临床治疗，B组在A组基础上给予孟鲁司特钠治疗、C组在A组基础上给予双歧杆菌四联活菌片治疗、D组在A组基础上施以孟鲁司特钠联合双歧杆菌四联活菌片治疗，4组患儿持续用药至出院后2个月。结果 A组患儿治疗有效率为66.67%，皮肤紫癜消失时间为（10.49±3.01）d，关节肿痛消失时间为（5.87±1.56）d，腹痛消失时间为（4.05±1.28）d，Alb水平为（27.11±7.80）mg/L，β2-MG水平为（0.31±0.15）mg/L，治疗后复发率为29.17%。D组患儿治疗有效率为91.67%、皮肤紫癜消失时间为（6.98±2.57）d，关节肿痛消失时间为（3.07±1.04）d，腹痛消失时间为（2.77±1.05）d，Alb水平为（22.00±8.47）mg/L，β2-MG水平为（0.19±0.06）mg/L，治疗后复发率为4.17%。D组患儿各指标与A组比较差异均有统计学意义（均P＜0.05）。B、C组患儿治疗有效率高于A组，但低于D组。B、C组患儿皮肤紫癜消失时间、关节肿痛消失时间、腹痛消失时间与A组比较差异无统计学意义（P＞0.05），与D组相比差异有统计学意义（P＜0.05）。结论 孟鲁司特钠联合双歧杆菌四联活菌片对小儿过敏性紫癜的疗效显著，能减少患儿不良反应发生，促进患儿恢复健康，值得临床推广。

Clinical effect of Montelukast Sodium combined with Bifidobacterium tetrabacteria in the treatment of allergic purpura in children

Abstract: Objective To analyze the clinical effect of montelukast sodium combined with Bifidobacterium tetrabacteria in the treatment of allergic purpura in children. Methods 96 children with Henoch-Schonlein purpura admitted to our hospital from March 1, 2015 to March 31, 2018 were randomly divided into group A, group B, group C or group D, with 24 cases in each group. Group A received conventional clinical treatment; Based on the conventional treatment, group B received montelukast sodium alone, group C received viable Bifidobacterium tetrabacteria alone, and group D received montelukast sodium combined with viable Bifidobacterium tetrabacteria. The treatments continued until 2 months after discharge. Results In group A, the efficiency rate was 66.67%, the time to disappearance of skin purpura was (10.49±3.01)d, the time to disappearance of joint swelling and pain was (5.87±1.56) d, the time to disappearance of abdominal pain was (4.05±1.28) d, the Alb index was (27.11±7.80) mg/L, the beta 2-MG index was (0.31±0.15) mg/L, and the recurrence rate was 29.17%. In group D, the efficiency rate was 91.67%, the times to disappearance of skin purpura, joint swelling and pain, and abdominal pain were (6.98±2.57) d, (3.07±1.04) d, and (2.77±1.05) d respectively, the Alb index was (22.00±8.47) mg/L, the beta 2-MG index was (0.19±0.06) mg/L, and the recurrence rate was 4.17%, significantly different from those in group A (all P<0.05). There was no significant difference in the times to disappearance time of the symptoms between groups B, C and A (all P>0.05). Conclusion Montelukast sodium combined with Bifidobacterium tetrabacteria has significant effect in the treatment of allergic purpura in children, which can reduce adverse reactions and promote the recovery of children.